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Abstract
Background: The status of the EGFR and HER2-neu genes has not been fully defined in ovarian
cancer. An integrated analysis of both genes could help define the proportion of patients that would
potentially benefit from targeted therapies.
Methods: We determined the tumour mutation status of the entire tyrosine kinase (TK) domain
of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer
as well as the gene copy number and protein expression of both genes in 31 of these patients by
DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).
Results: The EGFR was expressed in 59% of the cases, with a 2+/3+ staining intensity in 38%.
HER2-neu expression was found in 35%, with a 2/3+ staining in 18%. No mutations were found in
exons 18–24 of the TK domains of EGFR and HER2-neu. High polysomy of the EGFR gene was
observed in 13% of the invasive epthelial cancers and amplification of the HER2-neu gene was found
in 10% and correlated with a high expression level by immunohistochemistry.
Mutations within the tyrosine kinase domain were not found in the entire TK domain of both genes,
but have been found in very rare cases by others.
Conclusion: Genomic alteration of the HER2-neu and EGFR genes is frequent (25%) in ovarian
cancer. EGFR/HER2-neu targeted therapies should be investigated prospectively and specifically in
that subset of patients.
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Background
Most ovarian cancers originate in the surface epithelium
of the ovary and in particular from invaginations that are
remnants of previous ovulation sites. The ErbB family of
receptor tyrosine kinases plays a key role in normal ovar-
ian follicle development and cell growth regulation of the
ovarian surface epithelium [1].
Overexpression of EGFR (ErbB1) and HER2-neu (ErbB2)
has been reported in ovarian cancer [2] and both receptors
are commonly co-expressed [3]. In most studies overex-
pression of HER2-neu has been associated with a worse
prognosis while no clear prognostic significance has been
established for EGFR (ErbB1) expression [4-9].
Until now it has been unclear to what extent (over)
expression of these genes reflects constitutional activation
or merely reflects the physiological status of the normal
progenitor cells or whether other mechanisms of contitu-
tional activation exist in ovarian cancer.
The prognostic and predictive importance of these recep-
tors and their downstream signalling pathways has been
demonstrated in other malignancies and has led to the
development of targeted therapies such as monoclonal
antibodies (e.g cetuximab, panitunimab, trastuzumab)
and small molecules tyrosine kinase receptor inhibitors
(e.g gefitinib, erlotinib and more recently dual EGFR/
HER2-neu inhibitors such as lapatinib) in lung cancer,
colon cancer and breast cancer.
In breast cancer an increased copy number of HER2-neu
defines a patient population that benefits significantly
from treatment with trastuzumab and lapatinib.
In non-small cell lung cancer the presence of mutations in
the tyrosine kinase domain of EGFR observed in a minor-
ity of patients with adenocarcinoma, is a critical determi-
nant for tumour response to tyrosine kinase inhibitors
[10-13]. Some studies also identify a high EGFR copy
number and protein expression level as molecular predic-
tors of tyrosine kinase efficacy in non-small cell lung can-
cer (NSCLC) patients [14-17]. For other malignancies
such as glioblastomas and colorectal cancer, the predictive
significance of molecular markers for benefit from anti-
EGFR treatment with small molecule tyrosine kinase
inhibitors or monoclonal antibodies is proposed but
remains to be further defined [18-20].
These targeted therapies are also the subject of clinical tri-
als evaluating their potential in gynecological maligan-
cies.
In an unselected patient population with ovarian cancer
and primary peritoneal carcinoma [7] only a modest effect
(4% response rate) of gefitinib in an unselected patient
population was observed suggesting the need to identify
molecular markers that are predictive of response.
The EORTC is implementing a phase III clinical trial to
examine the effect of adjuvant treatment wit erlotinib in
unselected ovarian cancer patients in remission after first
line chemotherapy (EORTC protocol 55041).
The aim of the current study was to examine the status of
both the EGFR and HER2-neu genes with regard to the
mutational status, gene copy number and expression level
which could help to enrich for a patient population in
which the benefit from targeted therapies could be elec-
tively examined.
Methods
Design of the study
The study was done retrospectively on archived ovarian
tumour material. Data were compared to literature find-
ings.
Tissues
Archival ovarian tumour samples, collected from diagnos-
tic or resection specimens of 52 patients were included in
the analysis. The tissues were either fixed in Bouin and
paraffin embedded or fresh-frozen blocks. The presence of
adequate epithelial tumour tissue (80–100%) in each
block and characterization of tumours was determined by
a single pathologist (CB).
Mutational analysis
From some patients biopsies were available from more
than one disease site. Genomic DNA was thus extracted
from 68 fresh tissue samples obtained from the 52
patients after macrodissection by the same pathologist
(CB). Sections of the specimens used for DNA extraction
contained a majority proportion of tumour cells. Tissue
samples were first digested with proteinase K. DNA was
further purified by phenol-chloroform extraction and
sodium acetate-ethanol precipitation and subsequently
redissolved in a Tris-EDTA buffer. Exons 18–24 encoding
the tyrosine kinase domain of both EGFR and HER2-neu
genes were amplified by two rounds of polymerase-
chain-reaction assays with the use of Taq polymerase
(Applied Biosystems). The PCR primers were designed
with the help of the 'primer 3' program (Table 1 and 2).
PCR products were submitted to Denaturing Gradient Gel
Electrophoresis (DGGE), an electrophoretic separation
method based on differences in melting behavior of dou-
ble stranded DNA fragments that is recognized as very
sensitive for the detection of mutations [21].BMC Cancer 2008, 8:3 http://www.biomedcentral.com/1471-2407/8/3
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The power of this technique was evaluated and character-
ized in several aspects: (1) the hemi-nested PCR is very
sensitive since the DNA equivalent of 3 cells was sufficient
to generate an amplification signal (2) the DGGE can
detect a hemizygous mutation even when the mutant cells
used to prepare the DNA sample represented only 25% of
the total cellular amount in dilution experiments, and (3)
the 2 most prevalent somatic mutations found in the tyro-
sine kinase (TK) domain of EGFR (delE746-A750 in exon
19 and L858R in exon 21) in control samples (lung cancer
cell lines NCI- H1650 and H255) were consistently
detected with this technique. Corresponding white blood
cell DNA samples of most patients were available as con-
trols.
DNA fragments presenting an abnormal migration pat-
tern on DGGE were submitted to complete nucleotide
sequence analysis with the help of the DNA sequencing
kit (Sequenase version 2.0, Amersham) followed by
sequencing on gel (Life Technologies). Sequence data
were analyzed visually.
Immunohistochemistry and FISH analysis
Expression of EGFR (ErbB1) and HER2-neu (ErbB2) was
determined by immunohistochemistry with the use of the
EGFR PharmDx kit (Dako A/S, Glostrup, Denmark) and
the Herceptest™ (Dako A/S). Four micrometer sections of
each tumour block were cut. Tests were performed accord-
ing to the instructions of each kit including the appropri-
Table 2: HER2-neu primers
First step(5'—3') Second step(5'—3') Product Size(BP)
Exon18 F: ccagcactgacccaccac F: ccagcactgacccaccac 228
R: ctcttgcccctcccatca R: *agaactgccgaccacacc
Exon19 F: cccacgctcttctcactcat F: cccacgctcttctcactcat 183
R: agagaccagagcccagacct R: *gggtccttcctgtcctccta
Exon20 F: tgtggtctcccataccctct F: *ctctcagcgtacccttgtcc 230
R: caaagagcccaggtgcatac R: caaagagcccaggtgcatac
Exon21 F: tacatgggtgcttcccattc F: tacatgggtgcttcccattc 201
R:catgggctagacaccactcc R: *gctccttggtccttcaccta
Exon22 F: tagcccatgggagaactctg F: *ctccccacaacacacagttg 186
R: agctctcatcctccctccag R: agctctcatcctccctccag
Exon23 F: actcctgaccctgtctctgc F: actcctgaccctgtctctgc 220
R: ctttcatgccccttgtgg R: *aggacctcccaccctcct
Exon24 F: accagactggagggggagt F: *agaggcagcaagcacacag 203
R: gagggtgctcttagccacag R: gagggtgctcttagccacag
HER2-neu primers used for amplification (hemi-nested PCRs)
* indicates that a GC clamp was added at the 5' end of the primer,
GC clamp: cgcccgccgcgccccgcgcccggcccgccgcccccgcccg
Table 1: EGFR primers
First step (5'—3') Second step (5'—3') Product Size(BP)
Exon18 F: agcatggtgagggctgag F: *gctgaggtgacccttgtctc 258
R: acagcttgcaaggactctgg R: acagcttgcaaggactctgg
Exon19 F: catgtggcaccatctcaca F: catgtggcaccatctcaca 179
R: ccacacagcaaagcagaaac R: *ggtgtgtcgtttcgtctttg
Exon20 F: cgaagccacactgacgtg F: cgaagccacactgacgtg 244
R: ctatcccaggagcgcagac R: *ccgtatctcccttccctgat
Exon21 F: cctcacagcagggtcttctc F: cctcacagcagggtcttctc 215
R: aatgctggctgacctaaagc R: *ccgactggatttcg
Exon22 F: tttttccaacagagggaaact F: *cactgcctcatctctcacca 237
R:aaagaaaatacttgcatgtcagagg R:aaagaaaatacttgcatgtcagagg
Exon23 F: ccactgccttcttttcttgc F: *tttcttgcttcatcctctcag 205
R: cagctaggcagtgtggacag R: cagctaggcagtgtggacag
Exon24 F: gcatcaccaatgccttcttt F: *gcaatgccatctttatcatttc 200
R: actcttcccaatggaagcac R: actcttcccaatggaagcac
EGFR primers used for amplification (hemi-nested PCRs).
* indicates that a GC clamp was added at the 5' end of the primer,
GC clamp: cgcccgccgcgccccgcgcccggcccgccgcccccgcccgBMC Cancer 2008, 8:3 http://www.biomedcentral.com/1471-2407/8/3
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ate positive and negative controls. Both kits have been
studied in normal ovarian tissue which stains negative for
EGFR and HER2-neu.
Tumours were considered EGFR positive if a membranous
staining intensity of ≥ 1+ was observed in more then 1%
percent of the tumour cells (Dako EGFR pharmDX inter-
pretation guide and [22].
HER2-neu was interpreted according to the Herceptest ™
criteria and scored as 1+, 2+, 3+. HER2-neu overexpres-
sion was defined as weakly (2+) or strong (3+) when com-
plete membrane staining was observed in at least 10% of
the tumour cells.
Fluorescence in situ hybridization (FISH) analysis was
performed on cryosections using dual-color DNA FISH
probes: for the determination of EGFR gene copy number
a LSI EGFR (7p12) probe labeled with SpectrumOrange
was used in combination with a CEP7 centromeric probe
labeled with Spectrum Green (Abott Molecular, Des
Plaines, Il, USA). For the detection of HER2-neu amplifi-
cation a Pathvysion LSI Her-2 (17q11-12) probe labeled
with Spectrum Orange was used in combination with a
CEP 17 centromeric probe labeled with Spectrum Green
(Abott). Thirty-four samples were available for combined
FISH and immunochemistry analysis of EGFR.
EGFR copy number was scored as described by Cappuzzo
et al.[14].
For HER2-neu only the cases with a 2+/3+ immunohisto-
chemistry were submitted to FISH analysis (n = 6) based
on a known correlation established in breast cancer and
recent reports in ovarian cancer [9,23].
Amplification for both genes was defined as a ratio EGFR
or HER2-neu/CEP 7 ≥ 2.
Statistical analysis
Associations between factors were analyzed with a Fisher's
exact test. A p value of 0.05 was taken as the limit for sta-
tistical significance.
Results
Tumour characteristics
Fifty-two invasive epithelial ovarian tumours including 27
serous cystadenocarcinoma, 4 mucineus cystadenocarci-
noma and 21 endometroid carcinoma were characterized
for the presence of mutations in the entire tyrosine kinase
domain of both the EGFR and HER2-neu receptors using
DGGE and sequence analysis. Of thirty-one invasive can-
cers, sections containing adequate amounts and quality of
tumour were available to be examined for the expression
of EGFR and HER2-neu and gene copy number by immu-
nohistochemistry and FISH.
Mutation analysis
DNA samples were extracted from fresh tumour material
obtained from 52 patients. Previous studies done on DNA
from distinct tumour sites on part of the cases in this series
of ovarian cancers pointed to clonal heterogeneity within
the malignant cell population with regard to loss of chro-
mosome 11p [24]. Based on these observations it was
decided to examine DNA samples representing different
tumour sites when available. A total of 68 DNA samples
were thus available for mutation analysis. The complete
tyrosine kinase encoding domain was examined. No
somatic mutations were detected in exons 18–24 of both
receptors (Table 3). However, a variant DGGE migration
pattern was frequently observed for exon 23 of the EGFR
kinase domain. DNA sequencing revealed a point muta-
tion at position 2709 C>T in this exon. This is a silent
mutation (T903T) that does also not seem to influence
mRNA splicing [25]. Among the 52 tumours investigated,
13 were heterozygous for this genetic variant, while 3
appeared to be homozygotes. Analysis of blood DNA
samples available from 2 of these 3 patients could confirm
the homozygosity. We also found this genetic variant in
Table 3: EGFR and HER2-neu status of ovarian tumours
EGFR (ErbB-1) HER2-neu (ErbB-2)
Histopathological 
subtype (N = 52)
IHC (N = 31) FISH (N = 27) TKD Mutation 
(N = 68)
IHC (N = 31) FISH (N = 6) amplification TKD Mutation 
(N = 68)
0 1+ 2/3+ < 2 P 0 1+ 2/3+
Adenocarcinoma:
Serous 27 7 4 8 17 3 34 11 4 4 2 34
Mucinous 4 1 1 1 3 0 6 3 0 0 0 6
Endometroid 21 3 2 4 7 1 28 5 2 2 1 28
Fifty-two ovarian tumours were analyzed by immunohistochemistry, FISH and mutation status for EGFR (ErBb-1) and HER2-neu (ErBb-2). The IHC 
scores and definition of gene amplification are specified in the methods section. For EGFR no amplification was found. For HER2-neu the gene copy 
number was only examined in the 6 cancers with 2/3+ IHC.
N = number of cases, P = "high polysomy", 0 = absent, TKD = tyrosine kinase domain.BMC Cancer 2008, 8:3 http://www.biomedcentral.com/1471-2407/8/3
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the germline DNA of 5 out of 20 (25%) control individu-
als. Therefore the T903T variant is to be considered a
benign polymorfism frequently occuring in the Belgian
population.
Protein expression and gene copy number
EGFR immunostaining could be performed in adequately
preserved samples from 31 patients. Positivity was found
in 20/31 invasive epithelial cancers (64.5%) of which 13
(42 %) had an intensity of ≥ 2 (Table 3). FISH analysis for
EGFR could be interpreted in 27 invasive epithelial can-
cers. No gene amplification was found in any of the sam-
ples. In 4 cases (13%) an increased number of EGFR
copies (≥ 4 per nucleus) was detected in the presence of
polysomy for chromosome 7. Such cases were defined as
"high polysomy" as previously reported in NSCLC [14].
Immunohistochemistry on these polysomy cases yielded
variable results one case being 0, one case 1+ and two
cases 2+ for EGFR, giving no indication for a correlation
with the gene copy number (Fig 1).
HER2-neu immunostaining was positive (≥ 2+) in 6 out of
31 invasive epithelial cancers cases investigated (19 %) of
which three cases (10%) had an intensity of 3+ (Table 3).
Six tumours had 1+ IHC positivity. Only the cases with ≥
2+ immunohistochemistry were analyzed by FISH. In the
6 samples that showed either 2+ or 3+ positivity in immu-
nohistochemistry HER2-neu gene amplification by FISH
analysis was found in 3 cases (10%). One sample had a 2+
IHC score and 5 copies of the HER2-neu gene per nuclear
section; two of the cases with a 3+ IHC score had > 15 cop-
ies of the HER2-neu gene per nuclear section (Table 4 and
5).
One of the tumours with high level HER2-neu amplifica-
tion also stained intensily (3+) for EGFR without
increased gene copy number. One was EGFR 1+ and one
EGFR negative.
The tumours (n = 4) displaying high polysomy for EGFR
all stained negative for HER2-neu.
When the immunopositivity for EGFR and HER2-neu was
compared (Table 4) no statistically significant correlation
could be found between the expression levels An
Immunohistochemical and FISH analysis of EGFR and HER2-neu on ovarian tumours Figure 1
Immunohistochemical and FISH analysis of EGFR and HER2-neu on ovarian tumours. A-C : Immunohisto-
chemistry for EGFR and HER2-neu protein expression on paraffin sections from ovarian tumours (all 400× 
magnification). Examples of an EGFR score 0 (A), EGFR 3+ overexpression (B) and HER2-neu 3+ overexpression (C). D-F : 
Fluorescence in situ hybridisation for the EGFR and HER2-neu gene on frozen sections from ovarian tumours 
(all 630× magnification). Examples of a tumour without EGFR amplification (D), a tumour showing polysomy 7 (E) and a 
tumour with HER2-neu amplification showing clusters of multiple gene copies (F).
         
     
A C B
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increased gene copy number for either of these two genes
seems mutually exclusive (Table 5).
Discussion
We have examined the concordant gene status (mutation
status and copy number) and expression of both the
HER2-neu and EGFR in a series of epithelial ovarian
tumours. The mutational status of the genes could be
examined in 52 invasive cancers. The IHC was evaluable
in 31 and the FISH in 27 cancers.
Ovarian cancer has been examined in the past for some of
these characteristics, but in separate reports. The current
report is the first to examine the complete tyrosine coding
domain of both receptors in a series of ovarian cancers.
This analysis was complemented with the determination
of gene copy number and immunohistochemical expres-
sion in samples in which this was possible, giving compre-
hensive information in a single series of ovarian cancers
and for the two levels of relevance for prognostic or ther-
apeutic applications of these genes: protein expression
and gene status.
In breast cancer HER2-neu gene amplification is the major
determinant for a potential benefit from trastuzumab
treatment. In lung cancer studies [10,11,26] the majority
of cancer associated somatic mutations occur in the tyro-
sine kinase domain of EGFR and Her-2 neu mainly in
exon 18–21 and exon 19–20 respectively. Retrospective
and prospective data in lung cancer indicate that an EGFR
mutation is a stronger predictor for response and outcome
under treatment with tyrosine kinase inhibitors than
increased copy number [13,27,28].
In many studies in lung cancer, but also in other cancers,
EGFR mutation analysis has been restricted to the exons
known to be frequently mutated. This might be appropri-
ate in a context of determining potential sensitivity
towards small molecule tyrosine kinase inhibitors in a
clinical setting of lung cancer. However, when examining
other cancer types it remains to be determined whether
other mutations might occur. Therefore, we examined the
entire tyrosine kinase domain encoding exons (exons 18–
24) of both EGFR and HER2-neu in a cohort of ovarian
cancers. We have found no somatic mutations in 68 sam-
ples of 52 invasive epithelial cancers. Others have per-
formed mutation analysis limited to the exons of the
tyrosine kinase domain of EGFR known be mutated in
lung cancer. Recently 2 activating mutations in the tyro-
sine kinase domain of EGFR (exon19 (delE746-A750),
previously in NSCLC described have been reported in a
series of 57 ovarian adenocarcinomas. In one patient this
mutation correlated with an objective clinical response to
treatment with gefitinib [7].
In another recent study [29] including mutation analysis
of exon 18,19 or 21 of the EGFR TK domain in a series of
198 ovarian serous cystadenocarcinoma no mutation was
found. This brings the total number of invasive epithelial
ovarian cancer cases reported to 305 with a mutation rate
of 0.7 % when only the exons known to be mutated in
lung cancer are considered.
Activating and tyrosine kinase inhibitor (TKI) sensitizing
mutations in the EGFR gene are thus very rare in ovarian
cancer in contrast to adenocarcinoma of the lung in which
the mutation rate varies between 5 – 45% depending on
the phenotypic selection criteria and ethnic background
of patients [14,17].
All of our patients were of Caucasian origin and it remains
to be determined what the mutation rate would be in
other ethnicities, for example Asian.
We did not study the extracellular domain of the EGFR
receptor which is known to be mutated in glioma but also,
albeit rarely in squamous cell lung cancer [30].
HER2-neu mutations have been described in a small sub-
set (1.6 %) of lung cancers mainly in exon 19–20 [26,31].
These cancers and the patients in whom they occur have
the same phenotype as the cancers in which EGFR muta-
Table 5: EGFR and HER2-neu FISH results
EGFR (N = 27)
HER2-neu (N = 6) ≤ 2* High polysomy § Amplification**
≤ 2* 20 4 0
Amplification** 3 0 0
* Gene copy number, §as defined in []. 
** As defined in Methods.
Table 4: EGFR and HER2- neu immunohistochemical expression
N = 31 EGFR
HER2-neu 0 1+ 2+ 3+
07 461
1+ 2 2 2 1
2+ 1 2 0 0
3+ 1 0 1 1BMC Cancer 2008, 8:3 http://www.biomedcentral.com/1471-2407/8/3
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tions are found. The sigificance of these mutations with
regard to sensitivity to HER2-neu inhibition remains
undefined. One insertional mutation has been reported in
exon 20 of the tyrosine kinase domain of HER2-neu in a
series of 198 serous cystadenocarcinomas of the ovary
[29]. Thus the cumulative data in 248 invasive epithelial
ovarian cancers indicate a HER2-neu mutation rate of 0.4
%.
However the current report is again the only one that
examined the complete TK domain. EGFR expression was
observed in 64.5 % of invasive cancers, all adenocarcino-
mas, and in 13% percent of cases high polysomy as
defined in lung cancer was found. This proportion of high
polysomy is similar to that found by others [32] in pri-
mary ovarian cancers (9/64 or 14%). The cumulative data
in 98 patients thus indicate a 13% rate of high polysomy
of the EGFR gene in invasive epithelial ovarian cancer. The
classification used in other work [29] is less clear and it is
more uncertain what the potential biological significance
of low levels of polysomy could be.
No correlation was observed between EGFR expression
and EGFR gene copy number. This lack of correlation has
also been observed by others [29] and in NSCLC [14].
HER2-neu overexpression was found in 19 % in our
series, a proportion similar to other reports [33]. Three
tumour samples had a 3+ staining on immunohistochem-
istry of which two tumours had a high level of gene ampli-
fication. A third sample with a 2+ IHC positivity had a
lesser degree of gene amplification. This suggests that even
with this sample size a clear correlation can be detected
between expression level and gene copy number, as is also
observed in breast cancer. The HER2- neu gene amplifica-
tion rate is thus a non-negligible 10% in invasive ovarian
cancers. There are currently no other data available in
additional patient series. In breast cancer the gene status
has the greater relevance with regard to prognostic and
predictive implications. In breast cancer sometimes very
high (double-digit) levels of gene amplification can be
found in clinical samples, which has not been observed
yet in ovarian cancer.
The expression status of the EGFR and the HER2-neu
genes did not correlate although negativity for EGFR
seems to associate with negativity for HER2-neu while
vice-versa, negativity for HER2-neu can be associated with
high EGFR expression, reflecting the overall lesser positiv-
ity rate for HER2-neu versus EGFR. Constitutional activa-
tion of the genes through increased copy number seems
mutually exclusive.
What are the potential implications with regard to treat-
ment with HER family inhibitors in epithelial ovarian
cancer? Dramatic responses observed in lung cancer corre-
late strongly with the presence of EGFR tyrosine kinase
domain mutations. The absence of these mutations in all
but a very rare case of ovarian cancer probably will pre-
clude such dramatic responses upon treatment of ovarian
cancer with EGFR tyrosine kinase inhibitors. However,
these very rare (< 1 %) patients eventually also should
receive the opportunity to benefit from the exploration of
TKI treatment, which would require the cost of perform-
ing a mutation analysis in a large number of patients only
to identify rare cases, an effort that currently might not be
considered as cost-effective.
When considering the overall data available it can be
stated that the EGFR should be examined as a potential
target for treatment in a significant minority of ovarium
cancer patients and in particular for the 13% of patients
with a cancer having high polysomy. In the BR21 study in
NSCLC the strongest markers for survival benefit from
treament with erlotinib was EGFR expression and high
polysomy [13-17].
Clinical studies involving tyrosine kinase inhibitors in
ovarian cancer are ongoing [34] and in the one study that
has been published to date, analysis of EGFR gene copy
number by FISH or CISH was not included [7]. The lim-
ited data available suggest a potential progression-free
survival benefit. Four patients have been described with a
progression -free survival of over 6 months (9 – 32
months) including one patient carrying an EGFR muta-
tion [7].
If patients with high polysomy would benefit from anti-
EGFR treatment and in particular TKI in analogy to lung
cancer, and given the relatively low proportion of patients
having such a high polysomy in their tumours, then it is
to be feared that studies in unselected patient populations
will dilute out this beneficial effect. Even if these studies
are accompagnied by a retrospective analysis of these
biomarkers, the results might suffer from insufficient
power and biased sample analysis.
Therefore it is important to investigate the efficacy of
EGFR inhibitors in (ovarian) cancer in patients prospec-
tively selected for an altered gene status. In that context
more uniform definitions of gene amplification and poly-
somy need to be established. Different study groups tend
to use various definitions which makes a comparison of
data difficult [14,29].
Monoclonal antibodies (eg cetuximab) directed against
the extracellular EGFR domain do not seem to depend on
the presence of mutations in the tyrosine kinase domain
or gene amplification to induce responses in lung cancer
[35]. Currently none of the aspects of EGFR status exam-BMC Cancer 2008, 8:3 http://www.biomedcentral.com/1471-2407/8/3
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ined here has proven to be informative in predicting
response to treatment with these monoclonal antibodies
in other cancers [18-20,36].
Studies with these molecules have not been reported in
ovarian cancer despite the high rate of immunohisto-
chemical EGFR positivity.
HER2-neu is overexpressed in less than 1/5 of ovarian can-
cers. In patients selected for HER2-neu overexpression the
overall clinical benefit of trastuzumab has been limited
[37]. However, in breast cancer IHC expression is less rel-
evant than the gene copy number as assessed by FISH or
CISH.
If the analogy with breast cancer holds through, then
HER2-neu directed treatment could benefit the ten per-
cent of patients with invasive ovarian cancer identified as
having a true gene amplification in their cancer (this study
and [33]) and this should be explored prospectively again
in this selected population, both as single agent and in
combination with chemotherapy to investigate and
exploit synergies as observed in breast cancer.
Separately the value of HER2-neu kinase inhibition
should be evaluated in the very rare cases with a kinase
domain mutation [29].
Conclusion
We performed an integrated analysis of EGFR and HER2-
neu protein expression and gene status in a series of epi-
thelial ovarian cancers. Based on our findings and com-
bined with data from the literature it can be concluded
that EGFR/HER2-neu directed molecular treatments
could benefit and should be investigated in one fourth of
all invasive epithelial ovarian cancers.
The knowledge derived from retospective studies like this
one should be used in the design of prospective trials
investigating the value of EGFR/HER2-neu directed
molecular treatments in epithelial ovarian cancer includ-
ing the need for more uniform definitions of gene ampli-
fication and polysomy and selection of a patient
population with a known altered gene status.
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